AUG 5·SEC EDGARLow
Rosenberg Aaron sold $362K of ONC
Rosenberg Aaron (Chief Financial Officer) sold 1,157 shares of BeOne Medicines Ltd. (ONC) at $312.72 ($0.36M total) on 2026-08-03.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ONC
BeOne Medicines Ltd.
Price · $ONCvia TradingView
AI sentiment · 7d3 articles
- Bullish
- 3
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $208.2M 64 txs
OYLER JOHN61× · $207.0M
10b5-1 plan97%
Top stories · $ONCMore →
AUG 5·leaderpost.com
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
BeOne Medicines (NASDAQ: ONC) reported Q2 2026 revenue of $1.7B, up 30% y/y, led by BRUKINSA sales of $1.2B (+31%). GAAP diluted EPS was $2.05 per ADS and non-GAAP diluted EPS $3.84. The company raised 2026 revenue guidance to $6.6B-$6.8B and forecast high-80% gross margin, plus updated operating income ranges.
AUG 5·SEC EDGAR 8-K
BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition
BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti
ONC sentiment & insider activity
Over the past 7 days, alphai's AI scored 3 news stories mentioning ONC (BeOne Medicines Ltd.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent ONC coverage spans insider activity, earnings and corporate actions.
In the last 30 days, ONC insiders filed 64 SEC Form 4 transactions — no purchases and 64 sales ($208.2M). The most active reporter was OYLER JOHN, Chief Executive Officer, with 61 filings. 97% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving ONC
This is a routine insider sale disclosure with no stated 10b5-1 plan and zero shares remaining, which can modestly affect sentiment but is not a fundamental catalyst by itself.
Guidance raise plus strong Q2 revenue and margin/operating leverage signals improving fundamentals, likely supporting ONC’s near-term valuation and momentum.
Guidance raise plus strong Q2 operating leverage increases near-term earnings visibility and supports a bullish repricing risk for ONC.
The disclosed capex and capacity buildout is a positive operational signal, but it is not tied to near-term clinical or regulatory milestones.
This is a routine Form 4 insider sale with no 10b5-1 plan and the insider ends with 0 shares, which can modestly affect sentiment but not fundamentals.
alphai scores every news story that mentions ONC with an AI model for sentiment and relevance, and aggregates insider trades from BeOne Medicines Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ONC
Score
Rosenberg Aaron sold $362K of ONC
Rosenberg Aaron (Chief Financial Officer) sold 1,157 shares of BeOne Medicines Ltd. (ONC) at $312.72 ($0.36M total) on 2026-08-03.
2 min read
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
BeOne Medicines (NASDAQ: ONC) reported Q2 2026 revenue of $1.7B, up 30% y/y, led by BRUKINSA sales of $1.2B (+31%). GAAP diluted EPS was $2.05 per ADS and non-GAAP diluted EPS $3.84. The company raised 2026 revenue guidance to $6.6B-$6.8B and forecast high-80% gross margin, plus updated operating income ranges.
6 min readBeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition
BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti
6 min read
BeOne Committing $1 Billion+ To U.S. Drug Manufacturing Growth
BeOne Medicines (Nasdaq: ONC) said it will invest $300 million to expand its Princeton West Innovation Campus in Hopewell, New Jersey, adding small molecule manufacturing capacity. The expansion brings total U.S. investment to over $1 billion, creates about 120 jobs, adds 145,000 sq ft, and is expected to be fully operational in 2029.
4 min readLee Chan Henry sold $338K of ONC
Lee Chan Henry (SVP, General Counsel) sold 1,044 shares of BeOne Medicines Ltd. (ONC) at $323.69 ($0.34M total) on 2026-07-30.
1 min readLee Chan Henry sold $542K of BEIGF
Lee Chan Henry (SVP, General Counsel) sold 1,669 shares of BeOne Medicines Ltd. (BEIGF) at $325.00 ($0.54M total) on 2026-07-22 under a Rule 10b5-1 trading plan.
1 min readOYLER JOHN sold $34.6M of BEIGF
OYLER JOHN (Chief Executive Officer) sold 109,713 shares of BeOne Medicines Ltd. (BEIGF) at an average of $315.28 ($310.08–$320.06, $34.59M total) across 14 trades over 2026-07-20 to 2026-07-21 under a Rule 10b5-1 trading plan.
1 min readOYLER JOHN sold $20.2M of BEIGF
OYLER JOHN (Chief Executive Officer) sold 64,628 shares of BeOne Medicines Ltd. (BEIGF) at an average of $312.00 ($305.20–$315.06, $20.16M total) across 9 trades on 2026-07-17 under a Rule 10b5-1 trading plan.
2 min readOYLER JOHN sold $89.4M of BEIGF
OYLER JOHN (Chief Executive Officer) sold 283,154 shares of BeOne Medicines Ltd. (BEIGF) at an average of $315.56 ($310.02–$323.59, $89.35M total) across 17 trades over 2026-07-15 to 2026-07-16 under a Rule 10b5-1 trading plan.
2 min readOYLER JOHN sold $44.6M of BEIGF
OYLER JOHN (Chief Executive Officer) sold 145,861 shares of BeOne Medicines Ltd. (BEIGF) at an average of $305.95 ($303.07–$307.57, $44.63M total) across 6 trades on 2026-07-14 under a Rule 10b5-1 trading plan.
1 min read